Aidoc vs MedGenome

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Aidoc employs 300 people, while MedGenome has 200-500 employees.

Aidoc has raised more in total funding at $370M, compared to MedGenome's $50M — a gap of $320M. Combined, the two companies have completed 8 known funding rounds.

Aidoc holds the higher Awaira Score at 67/100, compared to MedGenome's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 4-point gap that reflects meaningful differences in scale or traction.

Aidoc was founded by Elad Walach in 2016. MedGenome was founded by Sam Santhosh in 2013. Visit each company's profile on Awaira for a full founder biography.

Aidoc: Aidoc is an Israeli artificial intelligence company founded in 2016 that develops clinical decision support software for radiology and medical imaging. The platform uses deep learning algorithms to analyze medical images, prioritize critical findings, and alert radiologists to potential abnormalities, particularly focusing on conditions requiring urgent intervention. Aidoc's core offering integrates into existing hospital workflows and PACS systems, enabling radiologists to identify and triage high-risk cases more efficiently. The company operates in the clinical AI segment, competing with firms like Zebra Medical Vision and Enlitic in automated imaging analysis. Aidoc's technology addresses the growing bottleneck of radiologist workload and diagnostic delays by automating preliminary image screening and flagging priority cases. The platform reportedly covers multiple pathologies including stroke, pulmonary embolism, and other acute conditions. As of the latest available data, Aidoc has secured $370 million in total funding through Series D stage, though its valuation remains not disclosed. The company has expanded internationally and serves healthcare institutions across multiple regions. Aidoc's growth trajectory reflects increasing institutional adoption of AI-assisted diagnostic tools in radiology departments globally, driven by workforce shortages and demand for faster diagnostic turnaround times in clinical settings. Aidoc focuses on clinical workflow integration rather than replacement, embedding AI directly into existing radiology infrastructure to accelerate diagnostic processes. MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system.

MedGenome was founded first in 2013, giving it 3 years of additional market experience. Aidoc was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Aidoc has approximately 300 employees, while MedGenome has approximately 200-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Aidoc and MedGenome are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.